Dapagliflozin + semaglutide
Intervention1 paper3 findingsPubChem 9887712PubChem 56843331ChEBI 85078ChEBI 167574
- Humans1
Outcomes
2High-density lipoprotein cholesterol
upin humans1Low certainty
1 study
High-density lipoprotein cholesterol
upin humans1Low certainty
Dapagliflozin + semaglutide increases high-density lipoprotein cholesterol in humans.
Humanscompared with dapagliflozin monotherapy6 months
Dapagliflozin Alone or Combined With Semaglutide: Cardiovascular and Renal Outcomes Among Patients With Type 2 Diabetes Mellitus in a 6-Month Real-World Retrospective Cohort Study in Saudi Arabia · Journal of the ASEAN Federation of Endocrine Societies · 13 Aug 2026
Estimated glomerular filtration rate
upin humans1Low certainty
1 study
Estimated glomerular filtration rate
upin humans1Low certainty
Dapagliflozin + semaglutide increases estimated glomerular filtration rate in humans.
Humanscompared with dapagliflozin monotherapy6 months
Dapagliflozin Alone or Combined With Semaglutide: Cardiovascular and Renal Outcomes Among Patients With Type 2 Diabetes Mellitus in a 6-Month Real-World Retrospective Cohort Study in Saudi Arabia · Journal of the ASEAN Federation of Endocrine Societies · 13 Aug 2026
Associations
1Heart failure
downin humans1RR 0.43Low certainty
1 study
Heart failure
downin humans1RR 0.43Low certainty
Dapagliflozin + semaglutide lowers the risk of heart failure in humans (RR = 0.43, p = 0.04).
Humanscompared with dapagliflozin monotherapy6 months
Dapagliflozin Alone or Combined With Semaglutide: Cardiovascular and Renal Outcomes Among Patients With Type 2 Diabetes Mellitus in a 6-Month Real-World Retrospective Cohort Study in Saudi Arabia · Journal of the ASEAN Federation of Endocrine Societies · 13 Aug 2026